The DOI matches its Crossref record; 240 of the 241 references it cites were found in a registry or an index.
Dementia in Down syndrome: unique insights for Alzheimer disease research
Open accessAbstract
Virtually all adults with Down syndrome (DS) show the neuropathological changes of Alzheimer disease (AD) by the age of 40 years. This association is partially due to overexpression of amyloid precursor protein, encoded by APP, as a result of the location of this gene on chromosome 21. Amyloid-β accumulates in the brain across the lifespan of people with DS, which provides a unique opportunity to understand the temporal progression of AD and the epigenetic factors that contribute to the age of dementia onset. This age dependency in the development of AD in DS can inform research into the presentation of AD in the general population, in whom a longitudinal perspective of the disease is not often available. Comparison of the risk profiles, biomarker profiles and genetic profiles of adults with DS with those of individuals with AD in the general population can help to determine common and distinct pathways as well as mechanisms underlying increased risk of dementia. This Review evaluates the similarities and differences between the pathological cascades and genetics underpinning DS and AD with the aim of providing a platform for common exploration of these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is substantial evidence of neuropathology from early in life in DS,6,9,10,21 including defects in neuronal development, an increased ratio of inhibitory to excitatory neurons, alterations in neuronal dendritic spines dynamics, activation of microglia, astrocyte reactivity, and elevated production of inflammatory cytokines in the brain.22,23,24,25”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Individuals with Down syndrome (DS), caused by trisomy of chromosome 21 (chr21, T21), are strongly predisposed to Alzheimer’s disease (AD), due to triplication of the APP gene, with ∼100% penetrance of AD brain pathology by age 40 and variable onset of dementia thereafter.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“People with DS are at greater risk for developing early-onset of dementia caused by AD.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Calcium's Role in Mechanotransduction during Muscle Development
Damm, T. B., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,552
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Sleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
Research works printed but not linked: 1
- Bertrand, I. & Koffas, D. Cas d’idioti mongolienne adulte avec nombreuses plaques senile et concretions calcaires pallidales. Rev. Neurol. 78, 338 (1946).
Cited by
Sorted by citations
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2024) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 483
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Self-citationFortea, J., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., Barroeta, I., Fernández, S., Altuna, M., Pegueroles, J., Montal, V., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30689-9 · Cited by 340
Aducanumab: Appropriate Use Recommendations
Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., & Weiner, M. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.41 · Cited by 316
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00413-4 · Cited by 306
Marzia Perluigi, A., Domenico, F. D., & Butterfield, D. A. (2023) · Physiological Reviews · doi:10.1152/physrev.00030.2022 · Cited by 322
Estimation of the number of people with Down syndrome in Europe
de Graaf, G., Buckley, F., & Skotko, B. G. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-00748-y · Cited by 211
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Jin, M., Xu, R., Wang, L., Alam, M. M., Ma, Z., Zhu, S., Martini, A. C., Jadali, A., Bernabucci, M., Xie, P., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.06.007 · Cited by 174
Self-citationRole of phosphodiesterases in the pathophysiology of neurodevelopmental disorders
Delhaye, S., & Bardoni, B. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00997-9 · Cited by 158
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Evolution of neuroinflammation across the lifespan of individuals with Down syndrome
Flores-Aguilar, L., Iulita, M. F., Kovecses, O., Torres, M. D., Levi, S. M., Zhang, Y., Askenazi, M., Wisniewski, T., Busciglio, J., & Cuello, A. C. (2020) · Brain · doi:10.1093/brain/awaa326 · Cited by 138
The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology
Handen, B. L., Lott, I. T., Christian, B. T., Schupf, N., O’Bryant, S. E., Mapstone, M. E., Fagan, A. M., Lee, J. H., Tudorascu, D., Wang, M., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12065 · Cited by 116
Self-citationMiyoshi, E., Morabito, S., Henningfield, C. M., Das, S., Rahimzadeh, N., Shabestari, S. K., Michael, N., Emerson, N., Reese, F., Shi, Z., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01961-x · Cited by 115
Self-citationFurther understanding the connection between Alzheimer's disease and Down syndrome
Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105
Self-citationDierssen, M., Fructuoso, M., de Lagrán, M. M., Marzia Perluigi, A., & Barone, E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00670 · Cited by 106
Alzheimer's Disease in the Down Syndrome: An Overview of Genetics and Molecular Aspects
Gomes, F. D. C., Mattos, M. F., Goloni‐Bertollo, E. M., & Pavarino, É. C. (2021) · Neurology India · doi:10.4103/0028-3886.310062 · Cited by 104
Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer’s disease
Young‐Pearse, T. L., Lee, H., Hsieh, Y., Chou, V., & Selkoe, D. J. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.03.005 · Cited by 104
GnRH replacement rescues cognition in Down syndrome
Manfredi-Lozano, M., Leysen, V., Adamo, M., Paiva, I., Rovera, R., Pignat, J., Timzoura, F. E., Candlish, M., Eddarkaoui, S., Malone, S. A., et al. (2022) · Science · doi:10.1126/science.abq4515 · Cited by 104
Young‐onset dementia diagnosis, management and care: a narrative review
Loi, S. M., Cations, M., & Velakoulis, D. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.51849 · Cited by 105
Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein
Gómez, W., Morales, R., Maracaja‐Coutinho, V., Parra, V., & Nassif, M. (2020) · Aging · doi:10.18632/aging.102677 · Cited by 94
Caldwell, A. L. M., Sancho, L., Deng, J., Bosworth, A., Miglietta, A., Diedrich, J. K., Shokhirev, M. N., & Allen, N. J. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01150-1 · Cited by 86
Proteomics Study of Peripheral Blood Mononuclear Cells in Down Syndrome Children
Lanzillotta, C., Greco, V., Valentini, D., Villani, A., Folgiero, V., Caforio, M., Locatelli, F., Pagnotta, S. E., Barone, E., Urbani, A., et al. (2020) · Antioxidants · doi:10.3390/antiox9111112 · Cited by 85
Im, E., Jiang, Y., Stavrides, P. H., Darji, S., Erdjument-Bromage, H., Neubert, T. A., Choi, J. Y., Wegiel, J., Lee, J.-H., & Nixon, R. A. (2023) · Science Advances · doi:10.1126/sciadv.adg1925 · Cited by 80
Alzheimer‐Related Cerebrovascular Disease in Down Syndrome
Lao, P. J., Gutierrez, J., Keator, D. B., Rizvi, B. M., Banerjee, A., Igwe, K. C., Laing, K. K., Sathishkumar, M. T., Moni, F., Andrews, H., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25905 · Cited by 76
Self-citationBrain insulin resistance triggers early onset Alzheimer disease in Down syndrome
Tramutola, A., Lanzillotta, C., Di Domenico, F., Head, E., Butterfield, D. A., Perluigi, M., & Barone, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104772 · Cited by 73
Self-citationFagan, A. M., Henson, R. L., Li, Y., Boerwinkle, A. H., Xiong, C., Bateman, R. J., Goate, A., Ances, B. M., Doran, E. W., Christian, B. T., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00139-3 · Cited by 70
Self-citation“Amyloid‐beta accumulation cycle” as a prevention and/or therapy target for Alzheimer's disease
Rao, C. V., Asch, A. S., Carr, D. J. J., & Yamada, H. Y. (2020) · Aging Cell · doi:10.1111/acel.13109 · Cited by 69
Pentz, R., Iulita, M. F., Ducatenzeiler, A., Bennett, D. A., & Cuello, A. C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0797-2 · Cited by 68
Martini, A. C., Helman, A. M., McCarty, K. L., Lott, I. T., Doran, E., Schmitt, F. A., & Head, E. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12113 · Cited by 66
Self-citationTorres, C. A. M., Wassouf, Z., Zafar, F., Sastre, D., Outeiro, T. F., & Schüle, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165724 · Cited by 64
Benejam, B., Videla, L., Vilaplana, E., Barroeta, I., Carmona‐Iragui, M., Altuna, M., Valldeneu, S., Fernández, S., Giménez, S., Iulita, M. F., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12047 · Cited by 68
Foret, M. K., Orciani, C., Welikovitch, L. A., Huang, C., Cuello, A. C., & Carmo, S. D. (2024) · Communications Biology · doi:10.1038/s42003-024-06552-4 · Cited by 63
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers
Janelidze, S., Christian, B. T., Price, J., Laymon, C., Schupf, N., Klunk, W. E., Lott, I., Silverman, W., Rosas, H. D., Zaman, S., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1740 · Cited by 60
Self-citationCalcium and activity-dependent signaling in the developing cerebral cortex
Arjun McKinney, A., Petrova, R., & Panagiotakos, G. (2022) · Development · doi:10.1242/dev.198853 · Cited by 55
Dissecting Alzheimer's disease pathogenesis in human 2D and 3D models
Cenini, G., Hebisch, M., Iefremova, V., Flitsch, L. J., Breitkreuz, Y., Tanzi, R. E., Kim, D. Y., Peitz, M., & Brüstle, O. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103568 · Cited by 60
Age‐stratified longitudinal study of Alzheimer's and vascular dementia patients
Jørgensen, I. F., Aguayo‐Orozco, A., Lademann, M., & Brunak, S. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12091 · Cited by 54
Venkataraman, L., Fair, S. R., McElroy, C. A., Hester, M. E., & Fu, H. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10068-9 · Cited by 55
Inborn Errors of Adaptive Immunity in Down Syndrome
Verstegen, R. H. J., & Kusters, M. (2020) · Journal of Clinical Immunology · doi:10.1007/s10875-020-00805-7 · Cited by 57
Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model
Sawa, M., Overk, C., Becker, A., Derse, D., Albay, R., Weldy, K., Salehi, A., Beach, T. G., Doran, E., Head, E., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12463 · Cited by 54
Self-citationNeurogenetic disorders across the lifespan: from aberrant development to degeneration
Hickman, R. A., O’Shea, S. A., Mehler, M. F., & Chung, W. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00595-5 · Cited by 59
Rafii, M. S., Sol, O., Mobley, W. C., Delpretti, S., Skotko, B. G., Burke, A. D., Sabbagh, M. N., Yuan, S. H., Rissman, R. A., Pulsifer, M., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0983 · Cited by 52
Porciúncula, L. O., Goto‐Silva, L., Ledur, P. F., & Rehen, S. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.674563 · Cited by 54
Moda, F., Ciullini, A., Dellarole, I. L., Lombardo, A., Campanella, N., Bufano, G., Cazzaniga, F. A., & Giaccone, G. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810255 · Cited by 49
Cryo-EM structures of amyloid-β and tau filaments in Down syndrome
Fernández, A., Hoq, M. R., Hallinan, G. I., Li, D., Bharath, S. R., Vago, F. S., Zhang, X., Ozcan, K. A., Newell, K. L., Garringer, H. J., et al. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01252-3 · Cited by 50
Pedrioli, G., & Paganetti, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.595515 · Cited by 50
Garic, D., McKinstry, R. C., Rutsohn, J., Slomowitz, R., Wolff, J. J., MacIntyre, L., Weisenfeld, L. A. H., Kim, S. H., Pandey, J., John, T. S., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.48341 · Cited by 49
Lanzillotta, C., Tramutola, A., Di Giacomo, G., Marini, F., Butterfield, D. A., Di Domenico, F., Perluigi, M., & Barone, E. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.01.042 · Cited by 47
Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
Montoliu‐Gaya, L., Strydom, A., Blennow, K., Zetterberg, H., & Ashton, N. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163639 · Cited by 46
Réthelyi, J., Vincze, K., Schall, D., Glennon, J. C., & Berkel, S. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105330 · Cited by 51
Alzheimer’s Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α
Sáez-Orellana, F., Octave, J., & Pierrot, N. (2020) · Cells · doi:10.3390/cells9051215 · Cited by 47
Proteostasis Decline and Redox Imbalance in Age-Related Diseases: The Therapeutic Potential of NRF2
Buttari, B., Tramutola, A., Rojo, A. I., Chondrogianni, N., Saha, S., Berry, A., Giona, L., Miranda, J. P., Profumo, E., Davinelli, S., et al. (2025) · Biomolecules · doi:10.3390/biom15010113 · Cited by 49
Lanzillotta, C., Zuliani, I., Tramutola, A., Barone, E., Blarzino, C., Folgiero, V., Caforio, M., Valentini, D., Villani, A., Locatelli, F., et al. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101892 · Cited by 46
Self-citationBasal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer’s Disease
Martinez, J. L., Zammit, M. D., West, N. R., Christian, B. T., & Bhattacharyya, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.703876 · Cited by 47
Deau, E., Lindberg, M. F., Miege, F., Roche, D., George, N. S., George, P. G., Krämer, A., Knapp, S., & Meijer, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00884 · Cited by 40
The Impact of Oxidative Stress on Pediatrics Syndromes
Micangeli, G., Menghi, M., Profeta, G., Tarani, F., Mariani, A., Petrella, C., Barbato, C., Ferraguti, G., Ceccanti, M., Tarani, L., et al. (2022) · Antioxidants · doi:10.3390/antiox11101983 · Cited by 46
Pentz, R., Iulita, M. F., Ducatenzeiler, A., Videla, L., Benejam, B., Carmona‐Iragui, M., Blesa, R., Lleó, A., Fortea, J., & Cuello, A. C. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12229 · Cited by 40
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40
Wu, Y., Lan, Y., Mao, J., Shen, J., Kang, T., & Xie, Z. (2023) · International Journal of Oral Science · doi:10.1038/s41368-023-00241-4 · Cited by 40
Bougea, A. M., & Gourzis, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164661 · Cited by 43
Clinical implications of immune‐mediated diseases in children with Down syndrome
Verstegen, R. H. J., Chang, K. J. J., & Kusters, M. (2019) · Pediatric Allergy and Immunology · doi:10.1111/pai.13133 · Cited by 39
Pires, G., McElligott, S., Drusinsky, S., Halliday, G. M., Potier, M., Wısnıewskı, T., & Drummond, E. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0848-6 · Cited by 41
Hartley, S. L., Handen, B. L., Devenny, D. A., Tudorascu, D., Piro‐Gambetti, B., Zammit, M. D., Laymon, C. M., Klunk, W. E., Zaman, S. H., Cohen, A. D., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12096 · Cited by 40
Doody, O., Hennessy, T., Moloney, M., Lyons, R., & Bright, A. (2022) · Journal of Clinical Nursing · doi:10.1111/jocn.16289 · Cited by 48
Stagni, F., & Bartesaghi, R. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.903729 · Cited by 33
Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome
Henson, R. L., Doran, E. W., Christian, B. T., Handen, B. L., Klunk, W. E., Lai, F., Lee, J. H., Rosas, H. D., Schupf, N., Zaman, S. H., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12057 · Cited by 34
Self-citationStress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules
Lanzillotta, C., & Domenico, F. D. (2021) · Biomolecules · doi:10.3390/biom11020266 · Cited by 36
The vexing complexity of the amyloidogenic pathway
Castro, M., Hadziselimovic, A., & Sanders, C. R. (2019) · Protein Science · doi:10.1002/pro.3606 · Cited by 40
Perluigi, M., Picca, A., Montanari, E., Calvani, R., Marini, F., Matassa, R., Tramutola, A., Villani, A., Familiari, G., Domenico, F. D., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12499 · Cited by 35
Larsen, F. K., Baksh, R. A., McGlinchey, E., Langballe, E. M., Benejam, B., Beresford‐Webb, J., McCarron, M., Coppus, A., Falquero, S., Fortea, J., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13779 · Cited by 34
Mechanisms and therapeutic potential of interactions between human amyloids and viruses
Michiels, E., Rousseau, F., & Schymkowitz, J. W. H. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03711-8 · Cited by 37
A qualitative study of the needs of older adults with intellectual disabilities
McCausland, D., Guérin, S., Tyrrell, J., Donohoe, C., O’Donoghue, I., & Dodd, P. C. (2021) · Journal of Applied Research in Intellectual Disabilities · doi:10.1111/jar.12900 · Cited by 33
Disentangling the Amyloid Pathways: A Mechanistic Approach to Etiology
Malmberg, M., Malm, T., Gustafsson, O., Sturchio, A., Graff, C., Espay, A. J., Wright, A. P. H., Andaloussi, S. E., Lindén, A., & Ezzat, K. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00256 · Cited by 30
The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer’s Cholinergic Atrophy
Carmo, S. D., Kannel, B., & Cuello, A. C. (2021) · Cells · doi:10.3390/cells11010016 · Cited by 35
Guest, F. L., Rahmoune, H., & Guest, P. C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-42667-5_8 · Cited by 34
Hendrix, J. A., Airey, D. C., Britton, A. F., Burke, A. D., Capone, G. T., Chavez, R., Chen, J. M., Chicoine, B. A., Costa, A. C. S., Dage, J. L., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091907 · Cited by 33
Self-citationZeilinger, E. L., Novaković, I. Z., Komenda-Schned, S., Franken, F., Sobisch, M., Mayer, A., Neumann, L. C., Loosli, S. V., Hoare, S., & Pietschnig, J. (2021) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2021.104148 · Cited by 34
Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome
Rueda, N., Flórez, J., Dierssen, M., & Martínez‐Cué, C. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.001 · Cited by 30
Pentz, R., Iulita, M. F., Mikutra-Cencora, M., Ducatenzeiler, A., Bennett, D. A., & Cuello, A. C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105150 · Cited by 31
Edwards, N. C., Lao, P. J., Alshikho, M. J., Ericsson, O. M., Rizvi, B. M., Petersen, M. E., O’Bryant, S. E., Aguilar, L. F., Simoes, S., Mapstone, M. E., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae331 · Cited by 34
Self-citationAmyloid Precursor Protein: A Regulatory Hub in Alzheimer's Disease
Chen, J., Chen, J.-S., Li, S., Zhang, F., Deng, J., Zeng, L., & Tan, J. (2023) · Aging and Disease · doi:10.14336/ad.2023.0308 · Cited by 34
Review of Artificial Intelligence Applications and Algorithms for Brain Organoid Research
Badai, J., Bu, Q., & Zhang, L. (2020) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-020-00386-4 · Cited by 30
Sáez-Orellana, F., Leroy, T., Ribeiro, F., Kreis, A., Leroy, K., Lalloyer, F., Baugé, E., Staels, B., Duyckaerts, C., Brion, J.-P., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150099 · Cited by 29
Alzheimer's disease amyloid-β pathology in the lens of the eye
Moncaster, J. A., Moir, R. D., Burton, M. A., Chadwick, O., Minaeva, O. V., Alvarez, V. E., Ericsson, M., Clark, J. I., McKee, A. C., Tanzi, R. E., et al. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.108974 · Cited by 30
Aβ and tau prions feature in the neuropathogenesis of Down syndrome
Condello, C., Maxwell, A. M., Castillo, E., Aoyagi, A., Graff, C., Ingelsson, M., Lannfelt, L., Bird, T. D., Keene, C. D., Seeley, W. W., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2212954119 · Cited by 27
Self-citationThe Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome
Zuliani, I., Lanzillotta, C., Tramutola, A., Francioso, A., Pagnotta, S. E., Barone, E., Marzia Perluigi, A., & Domenico, F. D. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00978-4 · Cited by 29
The Impact of Ageing on the CNS Immune Response in Alzheimer’s Disease
Chee, S. E. J., & Solito, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.738511 · Cited by 29
V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities
Falace, A., Volpedo, G., Scala, M., Zara, F., Striano, P., & Fassio, A. (2024) · Cells · doi:10.3390/cells13171441 · Cited by 27
Levman, J. E. D., MacDonald, A., Baumer, N., MacDonald, P., Stewart, N., Lim, A., Cogger, L., Shiohama, T., & Takahashi, E. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101874 · Cited by 29
Arenas, F., Castro, F., Núñez, S., Gay, G., García‐Ruiz, C., & Fernández-Checa, J. C. (2020) · Aging · doi:10.18632/aging.102641 · Cited by 28
Blood‐based biomarkers for Down syndrome and Alzheimer's disease: A systematic review
Petersen, M. E., & O’Bryant, S. E. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22714 · Cited by 27
Rastogi, M., Bartolucci, M., Nanni, M., Aloisio, M., Vozzi, D., Petretto, A., Contestabile, A., & Cancedda, L. (2024) · Neuron · doi:10.1016/j.neuron.2024.05.002 · Cited by 26
Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration?
Brackhan, M., Arribas-Blázquez, M., & Lastres‐Becker, I. (2023) · Antioxidants · doi:10.3390/antiox12081564 · Cited by 28
Alzheimer’s Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials
Rafii, M. S. (2020) · CNS Drugs · doi:10.1007/s40263-020-00740-6 · Cited by 26
Astroglial and microglial pathology in Down syndrome: Focus on Alzheimer's disease
Garcı́a, O., & Aguilar, L. F. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.987212 · Cited by 25
Hussain, F., Tahir, A., Jan, M. S., Fatima, N., Sadiq, A., & Rashid, U. (2024) · RSC Advances · doi:10.1039/d4ra00766b · Cited by 28
Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer’s-like mouse models
Kumar, S., Lemere, C. A., & Walter, J. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00959-w · Cited by 24
Vicente, M. C., Addo-Osafo, K., & Vossel, K. A. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1277613 · Cited by 25
Metadata
- Authors
- Lott, I. T., & Head, E.
- Affiliations
- University of California, Irvine (US)
- University of Kentucky (US)
- Corresponding author
- Lott, Ira T.
- Venue
- Nature Reviews Neurology
- Published
- 2019-02-07
- Volume
- 15
- Issue
- 3
- Pages
- 135-147
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC8061428
- OpenAlex
- W2914706199
- Cited by
- 383
- References
- 241
- Citations by year
- 2026: 35 · 2025: 58 · 2024: 61 · 2023: 45 · 2022: 57 · 2021: 66 · 2020: 46 · 2019: 15
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR001414)
- National Institute on Aging (P50AG016573, U01AG051412, U19AG068054, U24AG021886)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD064993)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Down syndrome, Alzheimer's disease, dementia, amyloid precursor protein, APP overexpression, chromosome 21, amyloid-beta deposition, epigenetic factors, disease progression, biomarkers, genetic risk profiles, neuropathology
- MeSH terms
- Alzheimer Disease, Down Syndrome, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
